• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for VUMERITY issued to BIOGEN INC

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIIB alert in real time by email
    New Drug Application (NDA): 211855
    Company: BIOGEN INC
    • Email

    Products on NDA 211855

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    VUMERITY DIROXIMEL FUMARATE 231MG CAPSULE, DELAYED RELEASE;ORAL Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 211855

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    10/29/2019 ORIG-1 Approval Type 2 - New Active Ingredient STANDARD Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211855Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    09/11/2024 SUPPL-17 Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211855s017lbl.pdf
    12/13/2023 SUPPL-16 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211855Orig1s016ltr.pdf
    03/22/2024 SUPPL-15 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211855s015lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/211855Orig1s015ltr.pdf
    11/16/2022 SUPPL-11 Manufacturing (CMC)-Packaging Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855Orig1s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211855Orig1s011ltr.pdf
    09/29/2022 SUPPL-10 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211855Orig1s010ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211855s010lbl.pdf
    02/10/2023 SUPPL-9 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211855Orig1s009ltr.pdf
    02/10/2022 SUPPL-6 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211855Orig1s006ltr.pdf
    01/29/2021 SUPPL-4 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211855s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211855Orig1s004ltr.pdf
    08/21/2020 SUPPL-2 Labeling-Package Insert, Labeling-Patient Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211855s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211855Orig1s002ltr.pdf

    Labels for NDA 211855

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    09/11/2024 SUPPL-17 Manufacturing (CMC) Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211855s017lbl.pdf
    03/22/2024 SUPPL-15 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211855s015lbl.pdf
    12/13/2023 SUPPL-16 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s016lbl.pdf
    02/10/2023 SUPPL-9 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s009lbl.pdf
    11/16/2022 SUPPL-11 Manufacturing (CMC)-Packaging Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855Orig1s011lbl.pdf
    09/29/2022 SUPPL-10 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855s010lbl.pdf
    02/10/2022 SUPPL-6 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211855s006lbl.pdf
    01/29/2021 SUPPL-4 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211855s004lbl.pdf
    08/21/2020 SUPPL-2 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211855s002lbl.pdf
    08/21/2020 SUPPL-2 Labeling-Patient Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211855s002lbl.pdf
    10/29/2019 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf
    Get the next $BIIB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIIB

    DatePrice TargetRatingAnalyst
    4/28/2025$118.00Buy → Hold
    HSBC Securities
    4/4/2025Buy → Hold
    Argus
    2/11/2025$160.00Mkt Perform
    Bernstein
    1/2/2025$315.00 → $138.00Overweight → Neutral
    Piper Sandler
    12/20/2024$230.00 → $164.00Outperform → Market Perform
    BMO Capital Markets
    12/16/2024$175.00Buy → Hold
    Stifel
    12/10/2024$178.00Neutral
    BofA Securities
    12/9/2024$250.00 → $180.00Buy → Hold
    Jefferies
    More analyst ratings

    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      5/5/25 4:17:10 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      2/20/24 9:13:26 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Pangalos Menelas N

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 5:05:17 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Minor Lloyd was granted 2,370 shares (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 4:54:06 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Patolawala Monish D was granted 2,370 shares, increasing direct ownership by 177% to 3,710 units (SEC Form 4)

      4 - BIOGEN INC. (0000875045) (Issuer)

      6/18/25 4:53:06 PM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

      9/16/24 6:52:10 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

      9/16/24 6:24:32 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for VUMERITY issued to BIOGEN INC

      Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

      3/25/24 4:41:37 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Biogen downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Biogen from Buy to Hold and set a new price target of $118.00

      4/28/25 8:32:10 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biogen downgraded by Argus

      Argus downgraded Biogen from Buy to Hold

      4/4/25 7:48:30 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bernstein initiated coverage on Biogen with a new price target

      Bernstein initiated coverage of Biogen with a rating of Mkt Perform and set a new price target of $160.00

      2/11/25 7:02:16 AM ET
      $BIIB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care